Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

NAActive, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
Acute Liver FailureDrug-Induced Liver Injury
Interventions
DRUG

N-Acetylcysteine (NAC) Treatment

Participants in this group received N-Acetylcysteine (NAC) at a dose of 140 mg/kg orally or via a nasogastric tube every 4 hours for the first 16 hours, followed by the same dose at intervals of 6-8 hours for a total of 3 days, alongside standard supportive care for acute liver failure.

OTHER

Standard supportive care

Participants in this group received only standard supportive care for acute liver failure, without N-Acetylcysteine (NAC). Standard supportive care included measures to prevent hypoglycemia, administration of broad-spectrum antimicrobials, proton pump inhibitors, fluid and electrolyte balance maintenance, and supportive treatment for hepatic encephalopathy.

Trial Locations (1)

54000

Lahore General Hospital, Lahore, Lahore

All Listed Sponsors
lead

Lahore General Hospital

OTHER_GOV

NCT06872372 - Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure | Biotech Hunter | Biotech Hunter